Entrada Therapeutics, Inc.
TRDA
$6.37
$0.111.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -32.64% | -19.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -32.64% | -19.52% | |||
| Cost of Revenue | 2.47% | -15.91% | |||
| Gross Profit | -3.94% | 15.75% | |||
| SG&A Expenses | 8.28% | -9.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.78% | -14.50% | |||
| Operating Income | -4.95% | 14.33% | |||
| Income Before Tax | -1.55% | 10.14% | |||
| Income Tax Expenses | -58.70% | -85.93% | |||
| Earnings from Continuing Operations | -1.41% | 11.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.41% | 11.26% | |||
| EBIT | -4.95% | 14.33% | |||
| EBITDA | -5.27% | 13.97% | |||
| EPS Basic | -0.84% | 11.56% | |||
| Normalized Basic EPS | -6.16% | 14.80% | |||
| EPS Diluted | -0.84% | 11.56% | |||
| Normalized Diluted EPS | -6.16% | 14.80% | |||
| Average Basic Shares Outstanding | 0.56% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.56% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||